-
1
-
-
84886698315
-
Innate and adaptive immune cells in the tumor microenvironment
-
Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013, 14:1014-1022.
-
(2013)
Nat Immunol
, vol.14
, pp. 1014-1022
-
-
Gajewski, T.F.1
Schreiber, H.2
Fu, Y.X.3
-
2
-
-
66149156276
-
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
-
Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009, 69:3077-3085.
-
(2009)
Cancer Res
, vol.69
, pp. 3077-3085
-
-
Harlin, H.1
Meng, Y.2
Peterson, A.C.3
Zha, Y.4
Tretiakova, M.5
Slingluff, C.6
-
3
-
-
77958012775
-
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy
-
Gajewski T.F., Louahed J., Brichard V.G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010, 16:399-403.
-
(2010)
Cancer J
, vol.16
, pp. 399-403
-
-
Gajewski, T.F.1
Louahed, J.2
Brichard, V.G.3
-
4
-
-
33745632047
-
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites
-
Harlin H., Kuna T.V., Peterson A.C., Meng Y., Gajewski T.F. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006, 55:1185-1197.
-
(2006)
Cancer Immunol Immunother
, vol.55
, pp. 1185-1197
-
-
Harlin, H.1
Kuna, T.V.2
Peterson, A.C.3
Meng, Y.4
Gajewski, T.F.5
-
5
-
-
33746214819
-
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site
-
Appay V., Jandus C., Voelter V., Reynard S., Coupland S.E., Rimoldi D., et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006, 177:1670-1678.
-
(2006)
J Immunol
, vol.177
, pp. 1670-1678
-
-
Appay, V.1
Jandus, C.2
Voelter, V.3
Reynard, S.4
Coupland, S.E.5
Rimoldi, D.6
-
6
-
-
0038181111
-
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma
-
Mortarini R., Piris A., Maurichi A., Molla A., Bersani I., Bono A., et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 2003, 63:2535-2545.
-
(2003)
Cancer Res
, vol.63
, pp. 2535-2545
-
-
Mortarini, R.1
Piris, A.2
Maurichi, A.3
Molla, A.4
Bersani, I.5
Bono, A.6
-
7
-
-
33749319703
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
-
Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
-
(2006)
Science
, vol.313
, pp. 1960-1964
-
-
Galon, J.1
Costes, A.2
Sanchez-Cabo, F.3
Kirilovsky, A.4
Mlecnik, B.5
Lagorce-Pages, C.6
-
8
-
-
84855225492
-
The immune score as a new possible approach for the classification of cancer
-
Galon J., Pages F., Marincola F.M., Thurin M., Trinchieri G., Fox B.A., et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012, 10:1.
-
(2012)
J Transl Med
, vol.10
, pp. 1
-
-
Galon, J.1
Pages, F.2
Marincola, F.M.3
Thurin, M.4
Trinchieri, G.5
Fox, B.A.6
-
9
-
-
84883863501
-
Up-regulation of PD-L1 IDO, and tregs in the melanoma tumor microenvironment is driven by CD8+ T cells
-
Spranger S., Spaapen R.M., Zha Y., Williams J., Meng Y., Ha T.T., et al. Up-regulation of PD-L1 IDO, and tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med 2013, 5(200):ra116.
-
(2013)
Sci Transl Med
, vol.5
, Issue.200
, pp. ra116
-
-
Spranger, S.1
Spaapen, R.M.2
Zha, Y.3
Williams, J.4
Meng, Y.5
Ha, T.T.6
-
10
-
-
84877072174
-
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
-
Gajewski T.F., Woo S.R., Zha Y., Spaapen R., Zheng Y., Corrales L., et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013, 25:268-276.
-
(2013)
Curr Opin Immunol
, vol.25
, pp. 268-276
-
-
Gajewski, T.F.1
Woo, S.R.2
Zha, Y.3
Spaapen, R.4
Zheng, Y.5
Corrales, L.6
-
11
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
-
(2010)
N Engl J Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
-
12
-
-
84862859820
-
Safety activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366(26):2443-2454. 10.1056/NEJMoa1200690.
-
(2012)
N Engl J Med
, vol.366
, Issue.26
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
13
-
-
84862769116
-
An immune-active tumor microenvironment favors clinical response to ipilimumab
-
Ji R.R., Chasalow S.D., Wang L., Hamid O., Schmidt H., Cogswell J., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61(7):1019-1031.
-
(2012)
Cancer Immunol Immunother
, vol.61
, Issue.7
, pp. 1019-1031
-
-
Ji, R.R.1
Chasalow, S.D.2
Wang, L.3
Hamid, O.4
Schmidt, H.5
Cogswell, J.6
-
14
-
-
80355136945
-
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells
-
Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011, 208(10):2005-2016.
-
(2011)
J Exp Med
, vol.208
, Issue.10
, pp. 2005-2016
-
-
Fuertes, M.B.1
Kacha, A.K.2
Kline, J.3
Woo, S.R.4
Kranz, D.M.5
Murphy, K.M.6
-
15
-
-
84873111794
-
Type I interferon response and innate immune sensing of cancer
-
Fuertes M.B., Woo S.R., Burnett B., Fu Y.X., Gajewski T.F. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013, 34(2):67-73.
-
(2013)
Trends Immunol
, vol.34
, Issue.2
, pp. 67-73
-
-
Fuertes, M.B.1
Woo, S.R.2
Burnett, B.3
Fu, Y.X.4
Gajewski, T.F.5
-
16
-
-
80355147292
-
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
-
Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011, 208:1989-2003.
-
(2011)
J Exp Med
, vol.208
, pp. 1989-2003
-
-
Diamond, M.S.1
Kinder, M.2
Matsushita, H.3
Mashayekhi, M.4
Dunn, G.P.5
Archambault, J.M.6
-
17
-
-
70349943834
-
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
-
Ishikawa H., Ma Z., Barber G.N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009, 461:788-792.
-
(2009)
Nature
, vol.461
, pp. 788-792
-
-
Ishikawa, H.1
Ma, Z.2
Barber, G.N.3
-
18
-
-
79953295544
-
The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity
-
Burnette B.C., Liang H., Lee Y., Chlewicki L., Khodarev N.N., Weichselbaum R.R., et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 2011, 71:2488-2496.
-
(2011)
Cancer Res
, vol.71
, pp. 2488-2496
-
-
Burnette, B.C.1
Liang, H.2
Lee, Y.3
Chlewicki, L.4
Khodarev, N.N.5
Weichselbaum, R.R.6
-
19
-
-
74549118938
-
The development of the tumor vascular-disrupting agent ASA404 (vadimezan DMXAA): current status and future opportunities
-
Head M., Jameson M.B. The development of the tumor vascular-disrupting agent ASA404 (vadimezan DMXAA): current status and future opportunities. Expert Opin Investig Drugs 2010, 19:295-304.
-
(2010)
Expert Opin Investig Drugs
, vol.19
, pp. 295-304
-
-
Head, M.1
Jameson, M.B.2
-
20
-
-
84882815198
-
Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA
-
Gao P., Ascano M., Zillinger T., Wang W., Dai P., Serganov A.A., et al. Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA. Cell 2013, 154:748-762.
-
(2013)
Cell
, vol.154
, pp. 748-762
-
-
Gao, P.1
Ascano, M.2
Zillinger, T.3
Wang, W.4
Dai, P.5
Serganov, A.A.6
-
21
-
-
84877795529
-
Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid
-
Conlon J., Burdette D.L., Sharma S., Bhat N., Thompson M., Jiang Z., et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol 2013, 190:5216-5225.
-
(2013)
J Immunol
, vol.190
, pp. 5216-5225
-
-
Conlon, J.1
Burdette, D.L.2
Sharma, S.3
Bhat, N.4
Thompson, M.5
Jiang, Z.6
-
22
-
-
84907495019
-
Therapeutic activity of high-dose intratumoral IFN-beta requires direct effect on the tumor vasculature
-
Spaapen R.M., Leung M.Y., Fuertes M.B., Kline J.P., Zhang L., Zheng Y., et al. Therapeutic activity of high-dose intratumoral IFN-beta requires direct effect on the tumor vasculature. J Immunol 2014, 193:4254-4260.
-
(2014)
J Immunol
, vol.193
, pp. 4254-4260
-
-
Spaapen, R.M.1
Leung, M.Y.2
Fuertes, M.B.3
Kline, J.P.4
Zhang, L.5
Zheng, Y.6
-
23
-
-
84892416698
-
Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses
-
Yang X., Zhang X., Fu M.L., Weichselbaum R.R., Gajewski T.F., Guo Y., et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 2014, 25:37-48.
-
(2014)
Cancer Cell
, vol.25
, pp. 37-48
-
-
Yang, X.1
Zhang, X.2
Fu, M.L.3
Weichselbaum, R.R.4
Gajewski, T.F.5
Guo, Y.6
-
24
-
-
84912120595
-
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors
-
Woo S.R., Fuertes M.B., Corrales L., Spranger S., Furdyna M.J., Leung M.Y., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41(5):830-842. 10.1016/j.immuni.2014.10.017.
-
(2014)
Immunity
, vol.41
, Issue.5
, pp. 830-842
-
-
Woo, S.R.1
Fuertes, M.B.2
Corrales, L.3
Spranger, S.4
Furdyna, M.J.5
Leung, M.Y.6
-
25
-
-
84912128872
-
STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors
-
Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41(5):843-852. 10.1016/j.immuni.2014.10.019.
-
(2014)
Immunity
, vol.41
, Issue.5
, pp. 843-852
-
-
Deng, L.1
Liang, H.2
Xu, M.3
Yang, X.4
Burnette, B.5
Arina, A.6
|